NCT00165841View on ClinicalTrials.gov

Maintenance Intermittent Therapy for Symptomatic GERD Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

December 31, 2005

Study Completion Date

June 30, 2008

Conditions
Gastroesophageal Reflux Disease
Interventions
DRUG

Rabeprazole 20 mg

rabeprazole sodium tablet 20 mg once daily

Trial Locations (1)

92085

Quality Care Medical Center Inc., Vista

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT00165841 - Maintenance Intermittent Therapy for Symptomatic GERD Patients | Biotech Hunter | Biotech Hunter